THE CANADA LANCET.

A NEW AND PROMISING AGENT FOR THE TREATMENT OF RHEUMATISM.

An announcement that is certain to cause widespread interest among the profession is being made in medical journals in behalf of Rheumatism Phylacogen. The new product is a bacterial derivative originated by Dr. A. F. Schafer, of California. The term "Phylacogen" (derived from two Greek words—the equivalent of "a guard" and "to produce") means "phylaxin producer," phylaxin being a name that is applied to a defensive proteid found in animals that have acquired an artificial immunity to a given infectious disease.

Rheumatism Phylacogen (Schaefr) is a sterile aqueous solution prepared from a large variety of pathogenic bacteria, such as the several staphylococci, Strepetococcus pyogenes, Bacillus pyocyaneus, Diplococcus pneumoniae, Bacillus typhosus, Bacillus coli communis, Streptococcus rheumaticus, Streptococcus erysipelatis, ets. The basic Phylacogen is a "polyvalent" preparation, since the organisms are obtained from cultures made at frequent intervals and from a variety of sources. To this basic material is added an equal amount of the filtrate obtained by similarly growing and treating the Streptococcus rheumaticus of Poynton and Paine. The product is indicated in all cases of rheumatism, acute and chronic, not due to gonorrheal infection. It is marketed in sealed glass vials of 10 Ce. capacity and may be administered subcutaneously or intravenously, the former method being preferred except in cases in which quick results are demanded.

Rheumatism Phylacogen, which is the first of a series of phylacogens originated by Dr. Shafer and about to be offered to the medical profession, has been thoroughly tested clinically in many of the leading hospitals, as well as by competent specialists and other scientific men in various parts of the country, and is said to have shown brilliant results in a large percentage of cases. With the co-operation of Dr. Schafer, and in accordance with his methods, it is prepared by Parke, Davis & Co., in whom are vested the sole rights of manufacture and sale. Physicians who are interested in this new treatment for rheumatism, and every general practitioner ought to be, will do well to get descriptive literature on the subject. It may be obtained by addressing the manufacturers at their principal laboratories in Walkerville, Ont. Ask for the "Rheumatism Phylacogen pamphlet" and mention this journal.

800